Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis: a critical appraisal. Wan MT, Takeshita J. Br J Dermatol 2020 May 14. doi: 10.1111/bjd.19216.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wan MT, Takeshita J. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis: a critical appraisal. Br J Dermatol 2020 May 14. doi: 10.1111/bjd.19216.
PMID: 32407562